Nanowear Inc.

Medical-grade Smart Textiles

ABOUT

TECHNOLOGY

Nanowear is the leading developer of patented, textile-based nanosensor technology with applications across a broad array of medical conditions and chronic disease states. The Company’s proprietary technology provides medical professionals with accurate and continuous diagnostic data through a wearable deployment that is cost-effective and unobtrusive to the patient. Real-time data is captured and transmitted wirelessly, streamlining the feedback process and driving outcomes. Nanowear’s core focus on innovation and next-gen technologies will continue to propel the Company towards exploring unique and groundbreaking applications for its nanosensor smart-textile technology.

INDUSTRY

Millions of individuals suffer from chronic diseases that are not only debilitating but also require continuous monitoring. Current monitoring applications fail to afford patients freedom of movement and peace of mind while at the same time providing medical practitioners with a flexible and cost-effective monitoring platform to make informed decisions. Nanowear is striving to bridge the gap and deliver ultimate diagnostic comfort and efficacy at a low cost.

HEADQUARTERS

Nanowear is headquartered in New York City and its research and development facility is located in University Park, Pennsylvania.

 

 

VISION

To be the world’s leading provider of nanosensor smart-textile technology by focusing on product development that not only enhances preventive health and well-being but also increases efficacy, efficiency and eliminates cost redundancies.

MISSION

To improve the quality of preventive medicine, practitioner productivity, patient care and physical performance through nanotechnology-enabled diagnostic monitoring.

 

VALUES


Commitment to innovation and development nurtured through an environment that encourages curiosity, collaboration and entrepreneurship.
Organizational support and respect for all employees, customers, suppliers and partners.
Assured delivery of best-in-class products and services that enrich the medical experience, support the highest quality of life and advance the community.
Sustainable financial growth and performance without sacrificing innovation and/or ethical standards.

TEAM

 

Managerial Advisors

 

Medical & Scientific Advisors

Robert Harbaugh M.D.

Robert Harbaugh M.D.

Distinguished Professor & Chairman of Neurosurgery, Penn State University

    Yoaav Krauthammer M.D.

    Yoaav Krauthammer M.D.

    Electrophysiologist, HealthEast Care System

      Mark Kronenfeld M.D.

      Mark Kronenfeld M.D.

      Vice Chairman of Dept. of Anesthesiology, Maimonides Medical Center

        David Theodoro M.D.

        David Theodoro M.D.

        Cardiac Surgeon & Chairman, Cardiovascular Dept., SSM Heart Institute

          PRESS

          December 1, 2016:

          Nanowear receives FDA clearance for its transformative remote diagnostic monitoring device differentiated by novel cloth-based nanosensor technology (SimplECG™)

          NEW YORK, NY – December 1, 2016 – Nanowear, an early stage developer of cloth-based diagnostic monitoring nanosensor technology, today announced that it has received FDA Class II 510(k) clearance for its first product, SimplECG™, a remote cardiac monitoring undergarment. SimplECG™ collects continuous multi-channel ECG, heart rate and respiratory rate data from the garment and transfers it to a web-based portal for review by a physician, by way of a mobile application. The initial version of the product is iPhone-based. Click for full press release…

          December 10, 2014:

          Nanowear Appoints Industry-Leading Experts to its Newly Formed Advisory Board

          NEW YORK, NY – December 10, 2014 – Nanowear, an emerging developer of wearable, textile-based diagnostic monitoring technology, today announced the appointment of leading medical and technology experts to its newly formed Advisory Board. The newly appointed Advisory Board will serve as a strategic resource to Nanowear as the Company continues product development and quality management in preparation for the U.S. Food and Drug Administration (FDA) approval process of its go-to-market product, a remote cardiac monitoring shirt for patients exhibiting symptoms of cardiovascular disease and potential ischemic events. Click for full press release…

           

          September 10, 2014:

          Nanowear Raises $1.5M Led by Social+Capital and MAS Holdings to Disrupt Remote Medical Diagnostic Monitoring

          NEW YORK, NY – September 10, 2014 – Nanowear Inc., an early-stage developer of wearable, textile-based diagnostic monitoring technology, today announced a $1.5M seed investment led by The Social+Capital Partnership and MAS Holdings (Pvt.) Limited, with several influential angels also participating in the round. The seed investment will fund production scaling and continued testing / validation of the company’s go-to-market product, a remote cardiac monitoring wearable base layer, in preparation for the U.S. Food and Drug Administration’s (FDA) approval process. Click for full press release...

           

           

           

          Contact

          Contact us to learn more about how Nanowear can increase physician efficiency and patient experience while reducing the costs associated with diagnostic monitoring.

          Thank you! I have received your message.

          name

          email

          message

          Contact Info

          info@nanowearinc.com

          New York, NY (HQ) | University Park, PA (R&D)